Patient reporting of adverse drug reactions: Useful information for pain management?

European Journal of Pain

Volumn 7, Issue 3, 2003, Pages 219-224

  Jarernsiripornkul, Narumol ^a   Krska, Janet ^b,d   Richards, R Michael E ^e   Capps, Phillip A G ^c  

^a KHON KAEN UNIVERSITY   (Thailand)

^b College of Pharmacy Practice ^*  (United Kingdom)

^c ROBERT GORDON UNIVERSITY   (United Kingdom)

^d Upper Toucks   (United Kingdom)

^e NONE

Author keywords

Adverse drug reactions; Pain management; Patient self reporting; Tramadol

Indexed keywords

ANALGESIC AGENT; TRAMADOL;

ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FATIGUE; FEMALE; FLUSHING; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OSTEOARTHRITIS; PAIN ASSESSMENT; PERCEPTION; PHYSICIAN; POSTAL MAIL; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; PUBLICATION; QUESTIONNAIRE; RATING SCALE; SELF REPORT; SIDE EFFECT; SLEEP DISORDER; SWEATING; SYMPTOM; TREATMENT WITHDRAWAL; UNITED KINGDOM; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0038707337     PISSN: 10903801     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1090-3801(02)00114-3     Document Type: Article

References (31)

1. Bateman DN, Sanders GL, Rawlins MD. Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol 1992;34:421-6.
2. Calis KA. Safety reporting in clinical trials. JAMA 2001;285:16.
3. Cossman M, Kohnen C. General tolerability and adverse event profile of tramadol hydrochloride. Rev Contemp Pharmacother 1995;6:513-31.
4. Cossman M, Kohnen C, Langford R, McCartney C. Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance. Drugs 1997;53(Suppl 2):50-62.
5. Crighton IM, Hobbs GJ, Wrench IJ. Analgesia after day case laparascopic sterilization: a comparison of tramadol with paracetamol/dextropropoxyphene and paracetamol/codeine combinations. Anaesthesia 1997;52:649-52.
6. Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs 1994;47(Suppl 1):3-7.
7. Donovan JL, Blake DR, Fleming WG. The patient is not a blank sheet: lay beliefs and their relevance to patient education. Br J Rheumatol 1989;29:58-61.
8. Egberts TCG, Smulders M, de Koning FHP, Meyboom RHB, Leufkens HGM. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. Br Med J 1996;313:530-1.
9. Fletcher AP. Approaching a century and after: morbidity and potentially drug induced disease. Adverse Drug React Toxicol Rev 1995;1:45-64.
10. Hopkins D, Shipton EA, Potgieter D, et al. Comparison of tramadol and morphine via subcutaneous PCA following major orthopaedic surgery. Can J Anaesth 1998;45:435-42.
11. Inman W, Pearce G. Prescriber profile and post-marketing surveillance. Lancet 1993;342:658-61.
12. Jarernsiripornkul N. Pharmacist input into patient self-reporting of adverse drug reactions. PhD thesis. Aberdeen: The Robert Gordon University; 1999.
13. Jarernsiripornkul N, Krska J, Richards RME, Capps PAG. Pharmacist-assisted patient-reporting of adverse drug reactions. Pharm J 1998;261:R33.
14. Jarernsiripornkul N, Krska J, Capps PAG, Richards RME, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 2002;53:318-25.
15. Lewis KS, Han NH. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm 1997;54:643-52.
16. Long W, Wynne HA. Patient satisfaction with arthritis medication. Int J Pharm Pract 1996;4:6-11.
17. Martin RM, Kappor KV, Wilton LV, et al. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. Br Med J 1998;317:119-20.
18. Micromedex Inc. Drugdex drug evaluation monographs [CD-ROM]; 1974-1998.
19. Mitchell AS, Henry DA, Hennrikus D, O'Connell DL. Adverse drug reactions: can consumers provide early warning?. Pharmacoepidemiol Drug Saf 1994;3:257-64.
20. Mitchell A, Henry DA, Sanson-Fisher R, O'Connell DL. Patients as a direct source of information on adverse drug reactions. Br Med J 1988;297:891-3.
21. Mitchell A, Henry D, O'Connell D, Hennrikus D. Consumer reports of clinical events - their contribution to adverse reaction monitoring. J Clin Res Drug Dev 1989;3:212.
22. Moore RA, McQuay HJ. Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain 1997;69:287-94.
23. Moore TJ, Psaty BM, Furberg CD. Time to act on drug safety. JAMA 1998;279:1571-3.
24. Read RW, Krska J. Targeted medication review: patients in the community with chronic pain. Int J Pharm Pract 1998;6: 216-22.
25. Ready LB, Sarkis E, Turner JA. Self-reported versus actual use of medication in chronic pain patients. Pain 1982;12:357-63.
26. Rogers AS, Israel E, Smith CR, et al. Physician knowledge, attitudes and behavior related to reporting adverse drug events. Arch Intern Med 1988;148:1596-600.
27. Royal Pharmaceutical Society Of Great Britain. From Compliance to Concordance. Achieving shared goals in medicine taking. London: The Royal Pharmaceutical Society of Great Britain; 1997.
28. Scott HD, Rosenbaum SE, Water WJ, et al. Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J 1987;70:311-6.
29. Sunshine A. New clinical experience with tramadol. Drugs 1994;47(Suppl 1):8-18.
30. Willison DJ, Gaebel KA, Borden EK, et al. Experience in the development of a postmarketing surveillance network: the pharmacy medication monitoring program. Ann Pharmacother 1995;29:1208-13.
31. van den Bemt PMLA, Egberst ACG, Lenderink AW, et al. Adverse drug events in hospitalized patients: a comparison of doctors, nurses and patients as a source of reports. Eur J Clin Pharmacol 1999;55:155-8.